文献速递膀胱癌与上尿路尿路上皮癌

上尿路尿路上皮癌根治性肾输尿管切除术后膀胱内肿瘤复发图谱及其对肿瘤学结局的影响

Bladder mapping of tumour recurrence after radical nephroureterectomy for upper tract urothelial carcinoma and its influence on oncological outcomes.
PubMed 文献 · BJU Int · 2019-01-06

本研究基于法国多中心回顾性数据库,纳入163例根治性肾输尿管切除术后发生膀胱内复发的上尿路尿路上皮癌患者,评估复发部位及膀胱袖口区复发的预测因素与预后影响。结果显示膀胱袖口区复发87例(53.4%),其他部位复发76例(46.6%),两组复发时间无显著差异;病理分期≥pT3与膀胱袖口区复发风险显著相关(P=0.03)。

要点

  • 根治性肾输尿管切除术后膀胱内复发以膀胱袖口区略多(53.4%),但无优势复发部位。
  • 病理分期≥pT3是膀胱袖口区复发的独立危险因素(P=0.03)。
  • 膀胱袖口区复发与其他部位复发的1、2、3年无复发生存概率无显著差异(P=0.35)。

核心结论

  • 根治性肾输尿管切除术后膀胱内复发在膀胱袖口区略多,但未发现优势复发部位。
  • 病理分期≥pT3与膀胱袖口区复发风险显著相关(P=0.03)。

研究设计与样本

  • 多中心回顾性研究,使用法国上尿路尿路上皮癌协作数据库,覆盖24个转诊泌尿肿瘤中心。
  • 纳入1995年至2010年间接受根治性肾输尿管切除联合膀胱袖口切除且发生膀胱内复发的患者,共163例。
  • 按复发部位分为膀胱袖口区复发组(A组,87例,53.4%)和其他膀胱部位复发组(B组,76例,46.6%)。

主要发现

  • 中位随访时间36个月(IQR 31.7–40.39),中位膀胱内复发时间10.0个月(IQR 8.6–13.39)。
  • A组中位复发时间11.0个月(IQR 8.8–13.2),B组10.0个月(IQR 8.5–11.5),组间无显著差异(P=0.35)。
  • 膀胱袖口区复发1、2、3年概率分别为45.5%(95%CI 40.1–50.9)、17.9%(95%CI 13.7–22.1)、10.8%(95%CI 7.4–14.2)。
  • 其他膀胱部位复发1、2、3年概率分别为42.1%(95%CI 36.4–47.8)、14.7%(95%CI 10.6–18.8)、4.4%(95%CI 1.9–6.9),组间无显著差异(P=0.35)。
  • 病理分期≥pT3与膀胱袖口区复发风险显著相关(P=0.03)。

关键数值与推荐

  • 病理分期≥pT3是膀胱袖口区复发的显著相关因素(P=0.03)。
  • 膀胱袖口区复发与其他部位复发的无复发生存概率无显著差异(P=0.35)。

临床怎么用

  • 根治性肾输尿管切除术后应关注膀胱袖口区复发,尤其对病理分期≥pT3的高危患者。
  • 术后膀胱内复发监测无需仅针对特定部位,应全面评估膀胱。

局限性

  • 回顾性研究设计可能存在选择偏倚和信息偏倚。
  • 样本量有限(163例),可能影响统计效能。
  • 随访时间中位数36个月,不足以评估长期复发模式。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the location of intravesical recurrence (IVR) after radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC), to determine the main predictive factors for IVR in the bladder-cuff area (BCA), and to assess the effect of BCA recurrence (BCAR) on prognosis. PATIENTS AND METHODS: This was a multicentre, retrospective study using the French collaborative database on UTUC, which includes data for all patients treated in 24 referral uro-oncology centres across the country. All patients who underwent RNU with bladder-cuff excision and who developed IVR between 1995 and 2010 were selected. Patients were divided into two groups: Group A: BCAR; and Group B: recurrence elsewhere in the bladder. The Kaplan-Meier method was used to estimate the probability of BCAR-free survival. Groups were compared using the log-rank test. Independent risk factors for BCAR were identified using a Cox proportional hazard regression model, with univariate and multivariate analyses. RESULTS: Overall, 163 patients were included in the final analysis: Group A, 87 patients (53.4%) and Group B, 76 (46.6%). The clinicopathological characteristics were similar in the groups. The median (interquartile range [IQR]) follow-up was 36 (31.7-40.39) months. The median (IQR) time to IVR was 10.0 (8.6-13.39) months [Group A: 11.0 (8.8-13.2) months vs Group B: 10.0 (8.5-11.5) months; P = 0.35]. The probability of BCAR at 1, 2, and 3 years was 45.5% (95% confidence interval [CI] 40.1-50.9), 17.9% (95% CI 13.7-22.1), and 10.8% (95% CI 7.4-14.2) respectively, whereas the probability of recurrence elsewhere in the bladder was 42.1% (95% CI 36.4-47.8), 14.7% (95% CI 10.6-18.8), and 4.4% (95% CI 1.9-6.9), respectively (P = 0.35). Pathological tumour stage (≥pT3) was significantly related to the risk of BCAR (P = 0.03). CONCLUSION: There were more BCARs after RNU in advanced UTUC. However, no preferred site for recurrence was detected.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Belhadj Y, Grande P, Seisen T, et al. Bladder mapping of tumour recurrence after radical nephroureterectomy for upper tract urothelial carcinoma and its influence on oncological outcomes. BJU Int. 2019. PMID: 30548115. doi:10.1111/bju.14647

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。